- ISIN
- US34962G1094
- CUSIP
- 34962G109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 13, 2017
Highlights
- EPS (TTM)
- -$3.50
- Gross Profit (TTM)
- -$55.00K
- EBITDA (TTM)
- -$52.49M
- Year Range
- $9.10 - $35.80
- Target Price
- $65.00
- ROA (TTM)
- -62.51%
- ROE (TTM)
- -84.84%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
FBRX Performance Chart
Forte Biosciences, Inc. (FBRX) is down 33.0% since the beginning of the year. At $18 per share, FBRX is trading 48.9% below its 52-week high of $36. Investors who bought $1,000 worth of FBRX shares 5 years ago would now be looking at an investment worth $20.
Loading charts...
Returns By Period
Forte Biosciences, Inc. (FBRX) has returned -32.97% so far this year and 24.69% over the past 12 months.
Forte Biosciences, Inc.
- 1D
- 2.41%
- 1M
- -15.33%
- YTD
- -32.97%
- 6M
- -37.67%
- 1Y
- 24.69%
- 3Y*
- -10.79%
- 5Y*
- -54.35%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
FBRX Monthly Returns History
Based on dividend-adjusted daily data since Apr 13, 2017, FBRX's average daily return is +0.04%, while the average monthly return is +2.42%. At this rate, an investment would double in approximately 2.4 years.
Historically, 41% of months were positive and 59% were negative. The best month was Nov 2024 with a return of +387.9%, while the worst month was Sep 2021 at -89.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 10 months.
On a daily basis, FBRX closed higher 46% of trading days. The best single day was Nov 20, 2024 with a return of +128.7%, while the worst single day was Sep 3, 2021 at -82.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.33% | 3.25% | -14.30% | 2.93% | -28.47% | -4.14% | -32.97% | ||||||
| 2025 | -30.03% | -42.73% | -14.73% | -5.93% | 16.44% | 52.12% | -22.82% | 10.22% | 36.36% | -13.73% | 43.43% | 46.93% | 20.08% |
| 2024 | -25.75% | 11.92% | 1.96% | 6.47% | -19.89% | -9.57% | 2.48% | -42.58% | -29.24% | -20.39% | 387.87% | 4.61% | 10.55% |
| 2023 | 0.00% | 2.00% | -0.98% | 5.94% | -4.67% | 1.96% | -2.88% | -17.81% | -20.25% | -25.83% | -3.46% | 73.35% | -17.83% |
| 2022 | -21.03% | -25.44% | 15.87% | -21.23% | 14.78% | -1.52% | -4.62% | 4.84% | -17.69% | 0.93% | -7.89% | 0.52% | -53.27% |
| 2021 | -7.00% | -15.86% | 20.29% | 5.60% | -1.80% | -5.40% | -10.89% | -1.80% | -89.94% | -8.45% | -1.85% | -19.55% | -94.12% |
Benchmark Metrics
Forte Biosciences, Inc. has an annualized alpha of -2.71%, beta of 0.93, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since April 13, 2017.
- This stock participated in 214.25% of S&P 500 Index downside but only 12.99% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -2.71%
- Beta
- 0.93
- R²
- 0.02
- Upside Capture
- 12.99%
- Downside Capture
- 214.25%
Return for Risk
Risk / Return Rank
FBRX ranks 54 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Forte Biosciences, Inc. (FBRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FBRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.78 | ||
| Sortino ratioReturn per unit of downside risk | -1.62 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.37 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | 0.44 | 2.78 | -2.34 |
| Martin ratioReturn relative to average drawdown | 1.07 | 12.44 | -11.37 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Forte Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Forte Biosciences, Inc. was 99.94%, occurring on Nov 1, 2024. The portfolio has not yet recovered.
The current Forte Biosciences, Inc. drawdown is 99.72%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -99.94%Nov 2024 | 7y 5mo | — | 9y 1moMay 2017 - now |
2017 pullback2017 | -5.08%Apr 2017 | 1d | 10d | 11dApr 2017 - May 2017 |
Drawdown Indicators
| FBRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.94% | -56.78% | -43.16% |
Max Drawdown (1Y)Largest decline over 1 year | -55.90% | -9.10% | -46.80% |
Max Drawdown (3Y)Largest decline over 3 years | -84.08% | -18.90% | -65.18% |
Max Drawdown (5Y)Largest decline over 5 years | -99.54% | -25.43% | -74.11% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.72% | -1.80% | -97.92% |
Average DrawdownAverage peak-to-trough decline | -81.78% | -10.71% | -71.07% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.83% | 2.03% | +21.80% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Forte Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Forte Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with FBRX
Add Forte Biosciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with FBRX